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of Recurrent Venous Thromboembolism
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Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND  58202-9037
Abstract
Introduction
• Venous thromboembolism (VTE) refers to the formation of a blood clot in a 
vein. The term VTE encompasses two types, deep vein thrombosis (DVT) 
and pulmonary embolism (PE). (American Heart Association, 2017)
• Virchow’s triad is a theory that helps describe the pathogenesis of VTE. The 
triad consists of alterations in blood flow (i.e. stasis), vascular endothelial 
injury, and hypercoagulable state. One or more of these risk factors can be 
identified in 80% of patients with VTE. (Bauer & Lip, 2018)
• Nearly 900,000 individuals in the United States are impacted by VTE each 
year. The estimated total annual healthcare cost for VTE can range from 
$7,594 to $16,644. (Beckman, Hooper, Critchley, & Ortel, 2010)
• It is thought that 60,000-100,000 will die from a VTE each year. About 
33% of people who have had a VTE will have a recurrence within 10 years. 
(Beckman et al., 2010)
• Warfarin has been the mainstay for VTE prophylaxis for many years, which 
can burden the patients with many drug and dietary interactions, as well as 
requires routine international normalized ratio (INR) therapeutic monitoring 
(Kreutz, 2014). 
• On the other hand, NOACs do not require regular therapeutic monitoring 
and have far fewer drug and dietary interactions (Kreutz, 2014). 
• For the purpose of this review, rivaroxaban will be the NOAC that is 
compared to warfarin because of the simplistic dosing regimen, requiring 
just once daily oral administration; other NOACs require twice daily oral 
administration. Warfarin also follows once daily oral administration.
Research Questions
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Discussion
• Increased medication costs of warfarin are offset by the increased risk of 
complications associated with warfarin, rendering rivaroxaban a more 
cost-effective alternative to warfarin.
• All reviewed studies found rivaroxaban to have a reduced risk of recurrent 
VTE compared to warfarin; all but one had strong quality of evidence. 
• Analysis of bleeding risk resulted in mixed results. Rivaroxaban was 
associated with reduced risk of bleeding, intracranial and extracranial, in 
about half of the studies. The others displayed no statistical difference in 
bleeding risk between rivaroxaban and warfarin. Due to mixed results, no 
definite conclusion can be made about bleeding risk.
• NOACs have always been limited by the lack of practical reversal agents. 
That aspect has recently changed with the release of an FDA approved 
agent, andexanet alpha. However, limited data is available on its efficacy 
and risks.
• Rivaroxaban is associated with no known dietary interactions and 
considerably reduced numbers of drug interactions, compared to warfarin.
• Rivaroxaban was associated with significantly higher rates of treatment 
compliance, when compared to warfarin.
The purpose of this systematic literature review is to determine the 
efficacy and safety of rivaroxaban (Xarelto) compared to warfarin 
(Coumadin), for the long term prophylaxis of recurrent venous 
thromboembolism (VTE). Rivaroxaban was chosen as the primary 
representative of factor Xa inhibitors because of its simplistic once a day 
dosing regimen. The PubMed database was extensively searched, using a 
variety of key terms, from September 10 to November 30, 2018. Works 
chosen include propensity-matched cohorts, retrospective studies, 
systematic reviews, and meta-analyses. All of which were published 
within the last 10 years; sources dated prior to 10 years were excluded. 
Studies with poor design or dual antiplatelet therapies were also grounds 
for exclusion. For this review, 11 resources were selected for analysis; 7 
additional resources were included for contextual information. Much of 
the research revealed that rivaroxaban is an adequate alternative for VTE 
prophylaxis, but the purpose of this research was to determine if its 
efficacy and safety is superior to that of warfarin. Despite statistically 
superior results for several aspects of rivaroxaban, an absence of distinct 
recommendations remain. The following results are intended to make the 
difficult decision of choosing an anticoagulant clearer for medical 
professionals and patients. 
• When treating patients with anticoagulants for prophylaxis of recurrent 
VTE, is there a statistical difference in efficacy and safety with rivaroxaban 
versus warfarin?
• When treating patients with anticoagulants for prophylaxis of recurrent 
VTE, is there a statistical difference in cost and adherence of therapy with 
rivaroxaban versus warfarin?
• When treating patients with anticoagulants, is there a statistical difference 
in potential drug and dietary interactions with rivaroxaban versus warfarin?
Comparison of costs 
• The mean medical cost reduction for those treated with rivaroxaban 
was -$2979 US (Amin et al., 2015) and -$2993 US (Seaman et al., 
2013), when compared to warfarin.
• Monthly medication costs were estimated at $39 per month for 
warfarin and $205 per month for rivaroxaban (Seaman et al., 2013).
Comparison of patient adherence to treatment
• The initial cost of rivaroxaban will be more, but it will be offset by 
additional costs that are associated with warfarin therapy; such as regular 
INR checks, increased risk of recurrent VTE, and decreased safety. 
• Due to the mixed results, bleeding risks were inconclusive, but current 
data suggests that rivaroxaban is associated with a reduced or at least 
equal risk. 
• NOACs have a potential drawback, which is the lack of a proven and 
affordable reversal agent. The recent release of andexanet alpha, a 
reversal agent for NOACs, appears promising. However, more 
information is needed to prove its efficacy and safety.
• Rivaroxaban is associated with far fewer drug interactions and has no 
known dietary interactions; unlike warfarin, which has many drug and 
dietary interactions. These qualities may be significant for patients with 
multiple comorbidities and/or those who do not maintain regular dietary 
habits, which may put them at risk recurrent VTE or bleeding events.
• Rivaroxaban was shown to have a significantly higher rate of adherence 
compared to warfarin, although a missed dose renders them completely 
unprotected because of a shorter half-life. 
• Rivaroxaban surfaced as a viable option for prevention of recurrent VTE. 
• Despite the evidence presented, the choice of agent is often the patients’ 
decision, but it is up to the medical professional to properly educate the 
patient. Offering this information will provide the patient an opportunity 
to make a well educated decision. However, it is undeniably easier to 
take the same dose every day, with no regular therapeutic monitoring.
• I would like to thank my advisor, Russell Kauffman, and instructor, Daryl 
Sieg, for their guidance during the development of this project.
• I would also like to thank Dawn Hackman, Dr. Marylin Klug, and Kirby 
Knutson for their assistance and expertise.
• Last of all, I cannot thank my family enough for their support and 
encouragement throughout the physician assistant program.
Statement of the Problem
The choice of agent for VTE prophylaxis, warfarin or NOACs, is a 
collective decision between the patient and provider. In the end, the 
choice of agent is often in the hands of the patient, and the decision is 
commonly based on cost and number of required clinic visits. Most 
prescribing providers have a general knowledge about the efficacy and 
safety of the two types of medications, but it often remains difficult to 
give a recommendation for one versus the other. Therefore, providers 
need to be informed on the latest studies to help differentiate which 
treatment is the best fit for a specific patient.
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Comparison of food and drug interactions
• There are over 120 known dietary and drug interactions with warfarin, 
and that list is expected to continuously grow. Rivaroxaban is 
associated with considerably reduced numbers of drug interactions 
and no known dietary interactions. (Nutescu et al., 2011)
Literature Review Cont’d
• Noncompliant patients on warfarin therapy were at a 2.6 times greater 
risk for recurrent VTE than compliant patients. A 43% higher risk of 
recurrent VTE was observed in patients who discontinued warfarin. 


























Comparison of efficacy and safety
• At 6 months, rivaroxaban was associated with reduced rates of GIB 
(HR 0.81, 95% CI 0.63–1.05) and markedly lower incidence of ICH 
(HR 0.21, 95% CI 0.09–0.62), when compared to warfarin. Similar 
results were seen at 3 months. (Coleman et al., 2018)
• In contrast, Raschi et al. (2016) found rivaroxaban to have no statistically 
significant protective effect for ICH, when compared to warfarin. Results 
also provided no statistically significant differences in risk of GIB, major 
bleeding, fatal bleeding, and clinically relevant bleeding, due to lack of 
consistency amongst included studies.
• Rivaroxaban therapy resulted in 65 ICH events, causing 34 deaths, and 
VKA therapy resulted in 108 ICH  events, causing 61 deaths. Also, 
rivaroxaban users had 36 extracranial bleeding events, resulting in 1 death; 
60 of such cases were reported with VKA therapy, resulting in 5 deaths. 
(Skaistis & Tagami, 2015) 
• Prins et al. (2013) concluded that rivaroxaban is noninferior (p < 0.001) 
compared to standard anticoagulation therapy, for the treatment of acute 
symptomatic DVT and/or PE. 
